Tudor Investment Corp ET AL Sells 39,388 Shares of Artivion, Inc. $AORT

Key Points

• Tudor Investment Corp cut its stake in Artivion by 36.7% in Q3, selling 39,388 shares and leaving it with 68,021 shares (about 0.14% of the company) valued at $2.88 million.
• Insiders have been net sellers, disposing of 133,043 shares worth roughly $4.98 million over the past three months (including sales by SVPs Marshall Stanton and Jean Holloway), leaving insiders with 7.60% ownership.
• Fundamentals and analyst view: Artivion beat Q results with $0.17 EPS vs. $0.14 expected and revenue up 19.2% to $118.3M; shares trade near $37.63 and analysts hold a "Moderate Buy" consensus with a $51 average price target.

Tudor Investment Corp ET AL cut its holdings in Artivion, Inc. (NYSE:AORT - Free Report) by 36.7% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 68,021 shares of the company's stock after selling 39,388 shares during the quarter. Tudor Investment Corp ET AL owned about 0.14% of Artivion worth $2,880,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Verition Fund Management LLC grew its stake in shares of Artivion by 1.6% during the 3rd quarter. Verition Fund Management LLC now owns 16,912 shares of the company's stock worth $716,000 after acquiring an additional 274 shares in the last quarter. State of Alaska Department of Revenue raised its stake in Artivion by 1.8% in the third quarter. State of Alaska Department of Revenue now owns 23,294 shares of the company's stock valued at $985,000 after buying an additional 414 shares during the period. PNC Financial Services Group Inc. lifted its holdings in Artivion by 6.2% during the 3rd quarter. PNC Financial Services Group Inc. now owns 8,232 shares of the company's stock valued at $349,000 after purchasing an additional 477 shares during the last quarter. Van ECK Associates Corp lifted its stake in shares of Artivion by 19.0% during the 3rd quarter. Van ECK Associates Corp now owns 3,176 shares of the company's stock worth $134,000 after buying an additional 506 shares during the last quarter. Finally, Oregon Public Employees Retirement Fund boosted its holdings in shares of Artivion by 5.8% during the third quarter. Oregon Public Employees Retirement Fund now owns 9,329 shares of the company's stock worth $395,000 after acquiring an additional 510 shares during the period. Institutional investors own 86.37% of the company's stock.

Insider Buying and Selling at Artivion

In related news, SVP Marshall S. Stanton sold 2,149 shares of the stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $37.78, for a total value of $81,189.22. Following the completion of the sale, the senior vice president directly owned 60,097 shares of the company's stock, valued at approximately $2,270,464.66. This represents a 3.45% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Jean F. Holloway sold 8,962 shares of the firm's stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $38.00, for a total transaction of $340,556.00. Following the transaction, the senior vice president directly owned 185,095 shares in the company, valued at $7,033,610. The trade was a 4.62% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 133,043 shares of company stock valued at $4,977,158 in the last three months. Insiders own 7.60% of the company's stock.

Artivion Trading Up 3.1%

NYSE AORT opened at $37.63 on Friday. The company has a market cap of $1.83 billion, a price-to-earnings ratio of 188.16 and a beta of 1.63. The business has a 50 day moving average price of $37.15 and a 200-day moving average price of $41.69. The company has a quick ratio of 2.62, a current ratio of 3.53 and a debt-to-equity ratio of 0.49. Artivion, Inc. has a 52 week low of $22.22 and a 52 week high of $48.25.

Artivion (NYSE:AORT - Get Free Report) last released its quarterly earnings data on Thursday, February 12th. The company reported $0.17 earnings per share for the quarter, beating analysts' consensus estimates of $0.14 by $0.03. Artivion had a net margin of 2.21% and a return on equity of 7.43%. The firm had revenue of $118.30 million for the quarter, compared to analyst estimates of $116.42 million. Artivion's revenue for the quarter was up 19.2% compared to the same quarter last year. As a group, equities analysts expect that Artivion, Inc. will post 0.37 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on AORT shares. Wall Street Zen raised shares of Artivion from a "hold" rating to a "buy" rating in a research report on Saturday. Needham & Company LLC reiterated a "buy" rating and issued a $58.00 price target on shares of Artivion in a research note on Tuesday. Weiss Ratings upgraded shares of Artivion from a "sell (d)" rating to a "hold (c-)" rating in a research report on Friday, February 20th. Stifel Nicolaus set a $55.00 target price on Artivion in a report on Thursday, March 5th. Finally, LADENBURG THALM/SH SH raised shares of Artivion from a "neutral" rating to a "buy" rating and set a $42.00 price target for the company in a research note on Friday. Seven research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $51.00.

About Artivion

Artivion, Inc NYSE: AORT is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.